See the DrugPatentWatch profile for livmarli
Yes, Livmarli Is Approved for Alagille Syndrome
Livmarli (maralixibat) is an FDA-approved oral solution for treating cholestatic pruritus in patients 3 months and older with Alagille syndrome (ALGS), a genetic disorder causing bile duct scarcity and severe itching.[1] Approval came in 2021 based on the ICONIC trial, which showed significant itch reduction.[2]
How Does Livmarli Work in Alagille?
Livmarli inhibits the ileal bile acid transporter (IBAT), reducing bile acid reabsorption in the gut. This lowers circulating bile acids, easing cholestasis and pruritus common in ALGS.[1][3] Dosing starts at 190 mcg/kg once daily, adjusted up to 380 mcg/kg based on response and tolerance.[1]
What About Other Indications for Livmarli?
It's also approved for progressive familial intrahepatic cholestasis (PFIC) in patients 3 months and older.[1] No approvals yet for broader liver conditions like primary biliary cholangitis, though trials explore expanded use.[4]
Common Side Effects and Patient Concerns
Patients report diarrhea (most frequent), abdominal pain, nausea, and rare severe cases like gastrointestinal bleeding or bone fractures.[1][5] Monitoring includes fat-soluble vitamin levels, as bile acid reduction can affect absorption. ALGS patients often see life-changing itch relief, but not all respond equally.[2]
Who Makes Livmarli and What's the Cost?
Mirum Pharmaceuticals markets it. List price is about $300,000 annually for a 30 kg child, though patient assistance programs cut costs for eligible families.[6] Patents extend exclusivity into the late 2030s; check DrugPatentWatch.com for expiry details.[7]
Alternatives if Livmarli Isn't Suitable
Options include bile acid sequestrants like cholestyramine, rifampin for itch, or ursodeoxycholic acid (UDCA). For severe cases, liver transplant remains standard. Kanuma (sebelipase alfa) targets related enzyme issues but not pruritus directly.[3][8]
Sources:
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214662s000lbl.pdf
[2] NEJM ICONIC Trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2102086
[3] Mirum Product Info: https://livmarli.com/
[4] ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04483531
[5] FDA Postmarketing: https://www.fda.gov/drugs
[6] GoodRx Pricing: https://www.goodrx.com/livmarli
[7] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/LIVMARLI
[8] AASLD Guidelines: https://www.aasldpubs.org/doi/10.1002/hep.31047